Pierre Mourlanette

A Randomized Non-Comparative Phase II Study of Anti-Programmed Cell Death-Ligand 1 Atezolizumab or Chemotherapy as Second-Line Therapy in Patients With Small Cell Lung Cancer: Results From the IFCT-1603 Trial

Jean-Louis Pujol, Laurent Greillier, Clarisse Audigier-Valette et al. · Journal of Thoracic Oncology · 2019 · 182 citations · Full text

Medicine, Oncology, Pharmacology +15

Randomized phase II–III study of bevacizumab in combination with chemotherapy in previously untreated extensive small-cell lung cancer: results from the IFCT-0802 trial

Jean-Louis Pujol, A. Lavolé, Élisabeth Quoix et al. · Annals of Oncology · 2015 · 97 citations · Full text

Medicine, Oncology, Pharmacology +10

IFCT-0401 Trial: A Phase II Study of Gefitinib Administered as First-Line Treatment in Advanced Adenocarcinoma with Bronchioloalveolar Carcinoma Subtype

J. Cadranel, Élisabeth Quoix, Laurence Baudrin et al. · Journal of Thoracic Oncology · 2009 · 58 citations · Full text

Medicine, Oncology, Pharmacology +9

OA 17.05 IFCT-1502 CLINIVO: Real-Life Experience with Nivolumab in 600 Patients (Pts) with Advanced Non-Small Cell Lung Cancer (NSCLC)

Olivier Molinier, Clarisse Audigier-Valette, J. Cadranel et al. · Journal of Thoracic Oncology · 2017 · 39 citations · Full text

Medicine, Oncology, Pharmacology +9

Differential effects of low and high-dose estradiol on airway reactivity in ovariectomized rats

Bruno Degano, Pierre Mourlanette, Séverine Valmary et al. · Respiratory Physiology & Neurobiology · 2003 · 29 citations

Medicine, Endocrinology, Pharmacology +14